January 26, 2023 5:01pm

Having gone against my own advice and gone out on a limb as GDP came above estimate while sudden dips intrigued me … the tide will be coming in!

Pre-Open Indication: 5 Hits and 3 MISS

Sad State of Share Value: Avrobio (AVRO) closed down again -$0.0206 with 511,978 shares traded. The many sessions since acknowledging the de-listing “issue” say a lot of addressing the NASDAQ issue. Just another “screw-job” of investors!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

 

If I have learned one thing as a former research analyst in a venture and public fund now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +205.57 points (+0.61%), the S&P closed UP +44.21 points (+1.10%) while the Nasdaq closed UP +199.06 points (+1.76%)

 

Henry’omics:

We need to more than consider the recessionary environment - rising rates and high inflation to comprehend the micro re “our” universe of cell and gene therapy companies

Indexes rose Thursday as traders combed through the latest batch of corporate earnings and Q4 GDP (gross domestic product) that came in above expectations.

Economic Data Docket: GDP data showed the economy expand at an annualized rate of 2.9% during Q4. That’s above the 2.8% estimate, but represents a slight cooldown from the Q3 reading.

 

Thursday’s … RegMed Investor’s (RMi) Pre-Open: “up, down, round and round goes the sector rope-tide to tan economic data driven market. My advice: open that portfolio envelope and think of a game of monopoly and follow RMi’s moves to recoup losses. As I have stated, “What goes up with ceremony, goes down with disdain followed by the opposite effect”. …https://www.regmedinvestors.com/articles/12804

 

Pre-Open Indications: 3 Miss < CRISPR Therapeutics (CRSP -$0.28), uniQure NV (QURE -$0.21), BioLife Solutions (BLFS -$0.35)> 5 Hits <Prime Medicine (PRME +$0.28), Sage Therapeutics (SAGE +$0.46), Solid Biosciences (SLDB +$0.11), Verve Therapeutics (VERV +$0.01), Ultragenyx (RARE +$0.74)>

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened –

  • Thursday’s advance/decline line opened negative at 8 up/ 24 down and 3 flats, stayed negative with 6 up/ 27 down and 2 flats at the mid-day, ending with a negative close of 11/23 and 1 flat.

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Thursday, the IBB was up +0.27% and the XBI was down -0.30%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -0.33 points or -1.73% at 18.75

 

Closing DOWN (10 of 23)

  • Chinook Therapeutics (KDNY -$1.16 after Wednesday’s +$0.13, Tuesday’s -$0.58 and Monday’s -$0.19)
  • Beam Therapeutics (BEAM -$0.59),
  • Intellia Therapeutics (NTLA -$0.39 after Wednesday’s +$0.49, Tuesday’s +$2.65 and Monday’s +$2.03),
  • Ionis Pharmaceuticals (IONS -$0.37 after Wednesday’s -$0.32, Tuesday’s +$0.65 and Monday’s -$1.34),
  • BioLife Solutions (BLFS -$0.35 after Wednesday’s -$0.85, Tuesday’s -$0.18 and Monday’s +$0.73),
  • AxoGen (AXGN -$0.34 after Wednesday’s -$0.51, Tuesday’s -$0.12 and Monday’s +$0.45),
  • CRISPR Therapeutics (CRSP -$0.28 after Wednesday’s -$1.21, Tuesday’s +$0.64 and Monday’s +$1.71),
  • Compass Therapeutics (CMPX -$0.26),
  • uniQure NV (QURE -$0.21 after Wednesday’s +$0.07, Tuesday’s +$0.41 and Monday’s -$0.77),
  • Bellicum Pharmaceuticals (BLCM -$0.12),
  • Voyager Therapeutics (VYGR -$0.10 after Wednesday’s -$0.39 after Tuesday’s +$0.32),

Flat (1):

  • Biostage (OTCQB: BSTG),

Closing Up (11 of 11):

  • Alnylam Pharmaceuticals (ALNY +$2.57 after Wednesday’s +$0.91, Tuesday’s -$2.48 and Monday’s +$0.94),
  • Ultragenyx (RARE +$0.74),
  • Sage Therapeutics (SAGE +$0.46 after Wednesday’s -$0.53 and Tuesday’s +$2.38),
  • Prime Medicine (PMRE +$0.28),
  • MiMedx (MDXG +$0.26),
  • Caribou Biosciences (CRBU +$0.14),
  • Solid Biosciences (SLDB $0.11 after Wednesday’s +$0.05 and Tuesday’s -$0.06),
  • Brainstorm Cell Therapeutics (BCLI +$0.09),
  • Verastem (VSTM +$0.0503),
  • Mesoblast (MESO +$0.02),
  • Verve Therapeutics (VERV +$0.01 after Wednesday’s -$0.49, Tuesday’s -$0.11 and Monday’s +$1.01),

 

Q1/23 – January

  • Thursday closed negative with 11 incliner, 23 decliners and 1 flat

 

The BOTTOM LINE: I try to keep it simple … and short!

Thursday’s sector dived, after four sector session ascensions.

So be cautious about adding exposure and stick to loss-cutting rules.

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

It’s just like counting the cards – something I WAS good at.

Upcoming Q4 earnings reporting will present challenges to share pricing.

 

Avrobio (AVRO) closed down again -$0.0206 with 511,978 shares traded after Wednesday’s -$0.0438 with 231,320 shares traded after Tuesday’s +$0.01 to $0.91 with 233,056 shares traded, Monday’s +$0.03 with 168,831 shares traded, Friday’s -$0.001 with 234,968 shares traded, and last Thursday’s +$0.04 with 303,682 share traded following the previous Wednesday’s -$0.0402 with 212,461 shares traded. <3-month average = 339,347 shares>

The many sessions since acknowledging the de-listing “issue” say a lot of addressing the NASDAQ issue <is their investment bank buying the shares?> as AVRO filed a S-3 for $250 million common stock, preferred stock, debt securities, warrants and unit offering within draft prospectus by Cowen as stock sinks while de-listing continues?

Just another “screw-job” of investors! < Read, SELL and Weep - see hyperlink below>

Avrobio (AVRO) files S-3 (Registration Statement) for offering with draft prospectus by Cowen … https://investors.avrobio.com/node/9116/html

·         Also, RA Capital has sold its position in the company – a sign of dissatisfaction!

·         While, President, CEO and director Geoff Mackay carries home a HUGE salary of $754.39 K per year?

 

Biostage (OTCQB: BSTG) closed flat again after Wednesday’s $0.00 with 2,054 shares traded after Tuesday’s -$0.09 with 2,275 shares traded after Monday’s +$0.03 with 713 shares traded (having been down most of the session), Friday’s flat with 30 shares traded, Thursday’s $0.00 with 32 shares traded, Wednesday’s -$0.07 with 421 shares traded and last Tuesday’s up +$0.60 with 3,047 shares traded <3-month average volume = 2,052 shares>

·         Review the trading pricing and volume versus the pump/promote agenda – somethings “wrong in Denmark” that’s Beijing, China for you – not following SEC rules?

·         This IND – now almost 4 years old without a clinical trial that will last 3-5 years for ADULT patients before BSTG can EVEN consider a pediatric venue!

·         They hired a CRO; hope they PAY them after all the difficulties the previous CRO went through and the same individuals from the past problems are STILL in charge!

·         Question; is this a Ponzi scheme as shares are bought to replace those sold??

 My question that resounds, that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.